Summary of the main results of TBTC Study 31/ACTG 5239 - Rifapentine and rifapentine plus moxifloxacin-containing 4 month treatment shortening regimens for pulmonary TB - Phase 3 randomized trial. The 4 month regimen containing both rifapentine plus moxifloxacin was non-inferior in safety and efficacy to the standard 6 month regimen in all primary, secondary and sensitivity analyses. The 4 month regimen containing rifapentine was not non-inferior to the standard 6 month regiment except in a sub-analysis population of patients with lesser forms of TB (low sputum smear grade or non-cavitary disease).
On August 20, 2019 researchers from the Uganda-CWRU Research Collaboration in Kampala, Uganda hosted a group of six health policy advisors and counsel or legislative aides for six US senators, including the office of Senator Robert Portman from Ohio, and representatives from the Global Health Technologies Coalition (GHTC) and the International AIDS Vaccine Initiative (IAVI) during a visit to learn about the impact of U.S. funding for global health research. The group visited the Collaboration's TB Project Clinic at Mulago Hospital where they were briefed about the Collaboration's 31 years of TB and TB+HIV epidemiologic studies and clinical trials, toured the clinic, and met with representatives from the local TB Community Research Advisory Group and patients from several of the Collaboration's TB studies. Professor Harriet Mayanja Kizza (CWRU '98) and Dean Moses Joloba (CWRU '96, '03) led the visit and gave brief presentations highlighting several key earlier clinical trials and their impact on TB prevention & treatment. Dr. Grace Muzanyi concluded with a brief presentation about TB Trials Consortium/ACTG A 5349, a large international study of new regimens to shorten treatment from 6 to 4 months for adolescents and adults with pulmonary TB. A Q&A and discussion was held at the end of the visit. The visitors commented on the substantial outputs from the research, the quality at which it has been conducted, and enjoyed interacting with the community TB group and former patients. The Collaboration was grateful for the opportunity to inform US government leadership about our TB and TB+HIV research.
CWRU THINK Magazine Spring/Summer 2019 - articles highlighting work with Uganda-CWRU Research Collaboration:
New Immune Markers of Exposure to MTB Challenge Decades of Clinical Practice - Results of TBRU's Work with Collaborators in Uganda, University of Washington and The Ragon Institute, May 2019
2016 Uganda-CWRU Anthropology-Engineering team - collaboration of Makerere and CWRU's social scientists and biomedical engineering faculty and students